4-phenylbutyric acid has been researched along with Parkinson Disease in 4 studies
4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In familial Parkinson's disease, accumulation of Parkin-associated endothelin receptor-like receptor (Pael-R), a substrate of ubiquitin ligase Parkin involved in ERAD, leads to ER stress and apoptosis." | 2.48 | [Molecular pharmacological studies on the protection mechanism against endoplasmic reticulum stress-induced neurodegenerative disease]. ( Kaneko, M, 2012) |
| " In a transgenic mouse model of diffuse Lewy body disease, long-term administration of phenylbutyrate reduces α-synuclein aggregation in brain and prevents age-related deterioration in motor and cognitive function." | 1.37 | Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. ( Bercury, K; Cummiskey, J; Freed, CR; Lebin, J; Luong, N; Zhou, W, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mimori, S | 1 |
| Koshikawa, Y | 1 |
| Mashima, Y | 1 |
| Mitsunaga, K | 1 |
| Kawada, K | 1 |
| Kaneko, M | 2 |
| Okuma, Y | 1 |
| Nomura, Y | 1 |
| Murakami, Y | 1 |
| Kanzaki, T | 1 |
| Hamana, H | 1 |
| Tiwari, S | 1 |
| Gupta, P | 1 |
| Singh, A | 1 |
| Chaturvedi, S | 1 |
| Wahajuddin, M | 1 |
| Mishra, A | 1 |
| Singh, S | 1 |
| Zhou, W | 1 |
| Bercury, K | 1 |
| Cummiskey, J | 1 |
| Luong, N | 1 |
| Lebin, J | 1 |
| Freed, CR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS[NCT04987671] | Phase 1/Phase 2 | 14 participants (Anticipated) | Interventional | 2021-08-05 | Active, not recruiting | ||
| Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy[NCT04937062] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2021-03-01 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for 4-phenylbutyric acid and Parkinson Disease
| Article | Year |
|---|---|
[Molecular pharmacological studies on the protection mechanism against endoplasmic reticulum stress-induced neurodegenerative disease].
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Apoptosis; Brain; Endoplasmic Reticulum | 2012 |
3 other studies available for 4-phenylbutyric acid and Parkinson Disease
| Article | Year |
|---|---|
Evaluation of synthetic naphthalene derivatives as novel chemical chaperones that mimic 4-phenylbutyric acid.
Topics: Cell Line, Tumor; Endoplasmic Reticulum Stress; Humans; Molecular Chaperones; Naphthalenes; Parkinso | 2015 |
4-Phenylbutyrate Mitigates the Motor Impairment and Dopaminergic Neuronal Death During Parkinson's Disease Pathology via Targeting VDAC1 Mediated Mitochondrial Function and Astrocytes Activation.
Topics: alpha-Synuclein; Animals; Astrocytes; bcl-2-Associated X Protein; Calcium; Caspase 3; Cytochromes; D | 2022 |
Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease.
Topics: Animals; Cells, Cultured; Histone Deacetylase Inhibitors; Mice; Neurons; Neuroprotective Agents; Onc | 2011 |
Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease.
Topics: Animals; Cells, Cultured; Histone Deacetylase Inhibitors; Mice; Neurons; Neuroprotective Agents; Onc | 2011 |
Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease.
Topics: Animals; Cells, Cultured; Histone Deacetylase Inhibitors; Mice; Neurons; Neuroprotective Agents; Onc | 2011 |
Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease.
Topics: Animals; Cells, Cultured; Histone Deacetylase Inhibitors; Mice; Neurons; Neuroprotective Agents; Onc | 2011 |